3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Neoplasm Metastasis
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Breast Diseases
1
Interventions
pembrolizumab
34
Cisplatin
30
Brachytherapy
16
Paclitaxel
15
Carboplatin
15
Bevacizumab
15
Radiotherapy
14
Blood Specimen Collection
13
Specimen Handling
12
Magnetic Resonance Spectroscopy
11
Colposcopy
11
Nivolumab
10
Drug Therapy
10
atezolizumab
8
Human Papillomavirus DNA Tests
8
Gemcitabine
8
lenvatinib
7
Radiation
6
Platinum
6
Biopsy
6
toripalimab
5
cemiplimab
5
Surveys and Questionnaires
5
Standard of Care
5
Radiotherapy, Intensity-Modulated
5
Practice Guidelines as Topic
5
Patient Navigation
5
Methods
5
Fulvestrant
5
Fluorodeoxyglucose F18
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uterine Cervical Neoplasms
×
STX-478
×
1 year
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled